Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Pediatr Gastroenterol Nutr. 2016 Nov;63(5):494–499. doi: 10.1097/MPG.0000000000001299

Table 4.

Comparison of patient characteristics by potential side effect recall.

Characteristic Recalled potential side effect P

No(n=67) Yes(n=55)
Female 35 (52%) 37 (67%) 0.09
Crohn’s disease 34 (51%) 30 (55%) 0.68
Aminosalicylates only 30 (45%) 11 (20%) 0.004
Any immunomodulator 16 (24%) 22 (40%) 0.06
Any biologic 24 (36%) 24 (44%) 0.38
Pediatric onset (diagnosis at < 18y old) 14 (21%) 12 (23%) 0.82
Disease duration (years since diagnosis) 10.0 (6.0, 15.0) 9.0 (5.0, 16.0) 0.81

P-value from Pearson chi-square test or Wilcoxon rank-sum test. Age at diagnosis is unknown for 2 patients, and disease duration is unknown for 12 patients.